Galectin Therapeutics director Marc Rubin resigns

Galectin Therapeutics Inc. reported that Marc Rubin resigned from its Board of Directors effective January 10, 2026.

Accepted by SEC EDGAR 01/12/2026 - 05:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Galectin Therapeutics Inc. reported that Marc Rubin resigned from its Board of Directors effective January 10, 2026. The company states that his resignation is not due to any disagreement with Galectin on its operations, policies, or practices, indicating an orderly governance change rather than a dispute-driven departure.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Galectin Therapeutics (GALT) disclose in this 8-K filing?

Galectin Therapeutics disclosed that Board member Marc Rubin resigned from the Board of Directors effective January 10, 2026.

Did Marc Rubin resign from Galectin Therapeutics due to a disagreement?

No. The company states that Marc Rubin’s resignation is not the result of any disagreement with Galectin on its operations, policies, or practices.

What is Marc Rubin’s role in relation to Galectin Therapeutics?

Marc Rubin served as a member of the Board of Directors of Galectin Therapeutics Inc. before submitting his resignation.

When was the Galectin Therapeutics director resignation effective?

The resignation of director Marc Rubin was effective on January 10, 2026.

Who signed the Galectin Therapeutics 8-K reporting the resignation?

The 8-K was signed on behalf of Galectin Therapeutics Inc. by Jack W. Callicutt, the company’s Chief Financial Officer.

Does the Galectin Therapeutics 8-K mention any operational impact from the director’s resignation?

The disclosure only states that Marc Rubin resigned and that it was not due to a disagreement; it does not describe specific operational impacts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false0001133416NASDAQ00011334162026-01-102026-01-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 10, 2026

GALECTIN THERAPEUTICS INC

(Exact name of registrant as specified in its charter)

Nevada	001-31791	04-3562325
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240

NORCROSS, GA 30071

(Address of principal executive office) (zip code)

Registrant’s telephone number, including area code: (678) 620-3186

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock $0.001 par value per share		GALT		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 10, 2026, Marc Rubin resigned from the Board of Directors of Galectin Therapeutics, Inc. (the “Company”). Mr. Rubin’s resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GALECTIN THERAPEUTICS INC.
Date: January 12, 2026	By:	/s/ Jack W. Callicutt
		Jack W. Callicutt
		Chief Financial Officer